NCT04961099Unknown1 期
Phase I Clinical Study on the Safety, Tolerance, Efficacy and Pharmacokinetics of Repeated Intratympanic HY01 in Patients With Sudden Sensorineural Hearing Loss
Heyu (Suzhou) Pharmaceutical Technology Co., Ltd1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2021年6月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Safety of HY01
研究概览
简要总结
Phase I clinical study on the safety, tolerance, efficacy and pharmacokinetics of repeated intratympanic HY01 in patients with sudden sensorineural hearing loss. In this study, low-dose group and high-dose group were designed, 6 cases in each group.
详细描述
The incidence rate of sudden deafness is increasing year by year, which can cause severe hearing loss. Intratympanic HY01 can increase the local drug concentration in the ear, which is equal to or better than that in the treatment of sudden sensorineural hearing loss, and reduce the systemic drug concentration at the same time. It has obvious clinical value for the treatment of hormone forbidden population.
HY01 is one of glucocorticoid drugs. In this study, we designed low-dose group and high-dose group of HY01, and enrolled 6 patients with sudden sensorineural hearing loss for salvage therapy in each group. HY01 will be administrated on D1, D4 and D7 . The trial will be ended 30 days after the first administration.
After determining the safety of low-dose, the patients in the high-dose group will be enrolled. The safety observation indexes included systemic Routine Indexes and otology indexes, and the efficacy and pharmacokinetics were observed at the same time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chinese subjects were 18-65 years old (including boundary value), male and female were not limited;
- •Patients with unilateral sudden deafness;
- •At least 7 days after the last medication (according to the guidelines for diagnosis and treatment of sudden deafness, the drugs allowed to be used include glucocorticoids, batroxobin, neurotrophic drugs (such as Mecobalamin, neurotrophic factors, etc.), antioxidants (such as lipoic acid, Ginkgo biloba extract, etc.) and lidocaine) ;
- •The hearing recovery of patients with sudden deafness after initial treatment is less than 15dB or less than 50% of the hearing of the affected ear or the healthy ear before the onset of the disease ;
- •19≤BMI<26kg/m2；
- •After at least one course of standard treatment (according to the guidelines for diagnosis and treatment of sudden deafness, systemic hormone combined with other drugs) ;
- •The informed consent was signed before the trial, and the trial content, process and possible adverse reactions were fully understood.
排除标准
- •Ear diseases
- •Patients with bilateral sudden deafness;
- •The initial treatment was intratympanic glucocorticoid;
- •The average hearing threshold of healthy ear was more than 25 dB;
- •Patients with previous or current ear related diseases may affect the judgment of adverse events, including but not limited to chronic ear infection, cholesteatoma, Meniere's disease, otosclerosis, fluctuating hearing loss, acoustic trauma, autoimmune hearing loss, radiation-induced hearing loss, syphilitic deafness, endolymphatic hydrops, hearing loss caused by otological surgery Suspected retrocochlear lesions, suspected perilymph fistula or membrane rupture, perilymph fistula or barotrauma, acoustic neuroma, synchronous tinnitus (possibly caused by glomus jugulare tumor), skull, face or temporal bone abnormalities;
- •Subjects with congenital deafness and hereditary deafness;
- •Treatment history of ototoxicity drugs within 6 months, such as chemotherapy, loop diuretics, aminoglycosides, quinine, high-dose aspirin, etc;
- •Subjects considered unsuitable for this clinical study.
- •Systemic diseases
- •Previous or current contraindications to glucocorticoids include hypertension, thrombosis, myocardial infarction, gastric and duodenal ulcer, visceral surgery, psychosis, electrolyte metabolism abnormality, glaucoma;
- •Previous or current patients with glucocorticoid caution include infection, ulcerative colitis, diverticulitis, postoperative enterostomy, liver cirrhosis, renal dysfunction, epilepsy, migraine, myasthenia gravis, osteoporosis, hypothyroidism, ocular herpes simplex, chickenpox or measles, recent live attenuated vaccine, latent tuberculosis or old tuberculosis Hepatitis B virus carriers;
- •Corticosteroid related psychiatric reactions;
- •It is forbidden to use this product for allergic patients, and it should be used with caution for subjects with allergic history to adrenocortical hormone drugs;
- •Subjects with positive TB history or tuberculin test (PPD);
- •Type 1 and type 2 diabetes;
- •pancreatitis;
- •Suffering from rheumatic diseases, such as rheumatoid arthritis, scleroderma, lupus, etc;
- •Previous or current use of chemotherapy or immunosuppressive drugs;
- •Active herpes zoster;
- •Those who had taken any medicine other than sudden deafness within 14 days before the first administration;
- •There was a history of alcohol abuse and drug abuse in one year before screening;
- •Those who had participated in any clinical trial within 3 months before the first administration of the trial;
- •Blood donation or blood loss ≥ 200ml within 3 months before the first administration;
- •Those who do not agree to avoid using alcohol, tobacco or caffeinated drinks within 24 hours before and during the trial, or to avoid strenuous exercise, or to avoid other factors affecting drug absorption, distribution, metabolism and excretion;
- •Pregnant or lactating women, or those whose plasma hCG test was positive, or those who could not or did not take contraceptive measures approved by the researcher within 6 months from the study period to the end of the study according to the guidance of the researcher;
- •Serological tests or other tests showed that subjects with positive hepatitis B, HCV, syphilis and AIDS were positive.
- •Subjects considered unsuitable for this clinical study.
研究组 & 干预措施
low-dose group
Experimental
low-dose group: HY01 10mg（20mg/ml）
干预措施: HY01 (Drug)
high-dose group
Experimental
high-dose group: HY01 20mg（40mg/ml）
干预措施: HY01 (Drug)
结局指标
主要结局
Safety of HY01
时间窗: Throughout the study approximately 30 days
AEs and SAEs
次要结局
- Hearing improvement(Day 30)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Repeat Dose Tolerance Study of Regadenoson in Healthy SubjectsHealthy VolunteersNCT01918995Astellas Pharma Global Development, Inc.36
招募中
1 期
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple SclerosisMultiple SclerosisNCT05532943Ever Supreme Bio Technology Co., Ltd.41
已完成
1 期
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot UlcersNeuropathic Diabetic Foot UlcersNCT02833389Genentech, Inc.72
已完成
1 期
An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic VolunteersObesityDiabetes MellitusNCT00806338Genaera Corporation22
已完成
1 期
Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected PatientsHIV InfectionsNCT05349968Shanxi Kangbao Biological Product Co., Ltd.24